The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1

CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of Pglycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples...

Full description

Bibliographic Details
Main Authors:	Teh, L. K., Mohammed, N.I, Salleh, M.Z., Rohaizak, M., Shahrun, N.S, Saladina, J.J., Shia, J.K.S., Roslan, H., Rajoo, T.S., Muniandy, S.P., Henry, G., Abdullah Ngow, Harris, Hla, K.T, Din, J
Format:	Article
Language:	English
Published:	Springer 2011
Subjects:	R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Online Access:	http://irep.iium.edu.my/18761/ http://irep.iium.edu.my/18761/ http://irep.iium.edu.my/18761/1/The_risk_of_recurrence_in_breast_cancer_patients_treated_with_Tamoxifen_Polymorphisms_of_CYP2D6_and_ABCB1.pdf

id	iium-18761
recordtype	eprints
spelling	iium-187612018-06-10T04:54:21Z http://irep.iium.edu.my/18761/ The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1 Teh, L. K. Mohammed, N.I Salleh, M.Z. Rohaizak, M. Shahrun, N.S Saladina, J.J. Shia, J.K.S. Roslan, H. Rajoo, T.S. Muniandy, S.P. Henry, G. Abdullah Ngow, Harris Hla, K.T Din, J R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer) CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of Pglycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples from 95 breast cancer patients treated with tamoxifen were collected and genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method. Recurrence risks were calculated using Kaplan–Meier analysis and compared using the log-rank test. Patients carrying CYP2D610/10 and heterozygous null allele (IM) showed higher risks of developing recurrence and metastasis (OR 13.14; 95% CI 1.57–109.94; P=0.004) than patients with CYP2D61/1 and 1/10 genotypes. Patients with homozygous CC genotypes of ABCB1 C3435T showed a shorter time to recurrence. Patients who were CYP2D6 IM and homozygous CC genotype of C3435T have statistically significant higher risks of recurrence (P=0.002). Similarly, median time to recurrence in these patients was only 12 months (95% CI=0.79–23.2) compared to those without this combination which was 48 months (95% CI=14.7–81.2). Patients with CYP2D6 IM and homozygous CC genotype of ABCB1 C3435T have shorter times to recurrence. The results confirmed the findings of previous studies and support FDA recommendation to perform pre-genotyping in patients before the choice of therapy is determined in breast cancer patients. Springer 2011-12-20 Article PeerReviewed application/pdf en http://irep.iium.edu.my/18761/1/The_risk_of_recurrence_in_breast_cancer_patients_treated_with_Tamoxifen_Polymorphisms_of_CYP2D6_and_ABCB1.pdf Teh, L. K. and Mohammed, N.I and Salleh, M.Z. and Rohaizak, M. and Shahrun, N.S and Saladina, J.J. and Shia, J.K.S. and Roslan, H. and Rajoo, T.S. and Muniandy, S.P. and Henry, G. and Abdullah Ngow, Harris and Hla, K.T and Din, J (2011) The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1. AAPS Journal, 14 (1). pp. 51-59. ISSN 1550-7416 DOI: 10.1208/s12248-011-9313-6
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English
topic	R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer)
spellingShingle	R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer) Teh, L. K. Mohammed, N.I Salleh, M.Z. Rohaizak, M. Shahrun, N.S Saladina, J.J. Shia, J.K.S. Roslan, H. Rajoo, T.S. Muniandy, S.P. Henry, G. Abdullah Ngow, Harris Hla, K.T Din, J The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
description	CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of Pglycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples from 95 breast cancer patients treated with tamoxifen were collected and genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method. Recurrence risks were calculated using Kaplan–Meier analysis and compared using the log-rank test. Patients carrying CYP2D610/10 and heterozygous null allele (IM) showed higher risks of developing recurrence and metastasis (OR 13.14; 95% CI 1.57–109.94; P=0.004) than patients with CYP2D61/1 and 1/10 genotypes. Patients with homozygous CC genotypes of ABCB1 C3435T showed a shorter time to recurrence. Patients who were CYP2D6 IM and homozygous CC genotype of C3435T have statistically significant higher risks of recurrence (P=0.002). Similarly, median time to recurrence in these patients was only 12 months (95% CI=0.79–23.2) compared to those without this combination which was 48 months (95% CI=14.7–81.2). Patients with CYP2D6 IM and homozygous CC genotype of ABCB1 C3435T have shorter times to recurrence. The results confirmed the findings of previous studies and support FDA recommendation to perform pre-genotyping in patients before the choice of therapy is determined in breast cancer patients.
format	Article
author	Teh, L. K. Mohammed, N.I Salleh, M.Z. Rohaizak, M. Shahrun, N.S Saladina, J.J. Shia, J.K.S. Roslan, H. Rajoo, T.S. Muniandy, S.P. Henry, G. Abdullah Ngow, Harris Hla, K.T Din, J
author_facet	Teh, L. K. Mohammed, N.I Salleh, M.Z. Rohaizak, M. Shahrun, N.S Saladina, J.J. Shia, J.K.S. Roslan, H. Rajoo, T.S. Muniandy, S.P. Henry, G. Abdullah Ngow, Harris Hla, K.T Din, J
author_sort	Teh, L. K.
title	The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_short	The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_full	The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_fullStr	The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_full_unstemmed	The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_sort	risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of cyp2d6 and abcb1
publisher	Springer
publishDate	2011
url	http://irep.iium.edu.my/18761/ http://irep.iium.edu.my/18761/ http://irep.iium.edu.my/18761/1/The_risk_of_recurrence_in_breast_cancer_patients_treated_with_Tamoxifen_Polymorphisms_of_CYP2D6_and_ABCB1.pdf
first_indexed	2023-09-18T20:27:56Z
last_indexed	2023-09-18T20:27:56Z
_version_	1777408542234378240

The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1

Similar Items